The chemopreventive effects of withaferin A were also observed in Akt-driven prostate tumorigenesis in the PTEN conditional knockout mouse model of prostate cancer, by administering the oral withaferin A at two different doses over 45 weeks. This evidence concerns the gene AKT1 and prostate cancer.